Baird Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.92M | Buy |
8,771
+2,260
| +35% | +$1.05M | 0.01% | 812 |
|
|
2025
Q4 | $2.95M | Sell |
6,511
-659
| -9% | -$284K | ﹤0.01% | 916 |
|
|
2025
Q3 | $2.81M | Sell |
7,170
-9,222
| -56% | -$3.85M | ﹤0.01% | 934 |
|
|
2025
Q2 | $7.3M | Buy |
16,392
+391
| +2% | +$180K | 0.01% | 600 |
|
|
2025
Q1 | $7.76M | Sell |
16,001
-370
| -2% | -$172K | 0.01% | 558 |
|
|
2024
Q4 | $6.59M | Sell |
16,371
-6,797
| -29% | -$3.15M | 0.01% | 600 |
|
|
2024
Q3 | $10.8M | Sell |
23,168
-30,595
| -57% | -$14.7M | 0.02% | 486 |
|
|
2024
Q2 | $25.2M | Sell |
53,763
-2,114
| -4% | -$918K | 0.05% | 278 |
|
|
2024
Q1 | $23.4M | Sell |
55,877
-12,134
| -18% | -$5.13M | 0.05% | 297 |
|
|
2023
Q4 | $27.7M | Buy |
68,011
+2,475
| +4% | +$914K | 0.06% | 263 |
|
|
2023
Q3 | $22.8M | Buy |
65,536
+2,614
| +4% | +$914K | 0.06% | 262 |
|
|
2023
Q2 | $22.1M | Buy |
62,922
+14,075
| +29% | +$4.74M | 0.06% | 279 |
|
|
2023
Q1 | $15.4M | Sell |
48,847
-11,360
| -19% | -$3.41M | 0.04% | 347 |
|
|
2022
Q4 | $17.4M | Buy |
60,207
+4,055
| +7% | +$1.24M | 0.05% | 323 |
|
|
2022
Q3 | $16.3M | Buy |
56,152
+707
| +1% | +$203K | 0.05% | 322 |
|
|
2022
Q2 | $15.6M | Sell |
55,445
-6,364
| -10% | -$1.7M | 0.04% | 350 |
|
|
2022
Q1 | $16.1M | Sell |
61,809
-14,219
| -19% | -$3.37M | 0.04% | 353 |
|
|
2021
Q4 | $16.7M | Buy |
76,028
+1,838
| +2% | +$357K | 0.04% | 355 |
|
|
2021
Q3 | $13.5M | Buy |
74,190
+11,661
| +19% | +$2.28M | 0.03% | 370 |
|
|
2021
Q2 | $12.6M | Buy |
62,529
+7,276
| +13% | +$1.52M | 0.03% | 375 |
|
|
2021
Q1 | $11.9M | Buy |
55,253
+3,208
| +6% | +$705K | 0.03% | 374 |
|
|
2020
Q4 | $12.3M | Buy |
52,045
+10,616
| +26% | +$2.44M | 0.04% | 354 |
|
|
2020
Q3 | $11.3M | Buy |
41,429
+6,575
| +19% | +$1.81M | 0.04% | 345 |
|
|
2020
Q2 | $10.1M | Sell |
34,854
-6,868
| -16% | -$1.86M | 0.04% | 341 |
|
|
2020
Q1 | $9.92M | Sell |
41,722
-3,670
| -8% | -$842K | 0.05% | 324 |
|
|
2019
Q4 | $9.94M | Buy |
45,392
+12,017
| +36% | +$2.43M | 0.04% | 379 |
|
|
2019
Q3 | $5.65M | Buy |
33,375
+1,509
| +5% | +$267K | 0.02% | 475 |
|
|
2019
Q2 | $5.84M | Buy |
31,866
+5,194
| +19% | +$908K | 0.02% | 471 |
|
|
2019
Q1 | $4.91M | Buy |
26,672
+5,772
| +28% | +$1.07M | 0.03% | 450 |
|
|
2018
Q4 | $3.46M | Buy |
20,900
+16,947
| +429% | +$2.94M | 0.02% | 495 |
|
|
2018
Q3 | $758K | Sell |
3,953
-1,284
| -25% | -$229K | ﹤0.01% | 923 |
|
|
2018
Q2 | $890K | Buy |
5,237
+258
| +5% | +$40K | 0.01% | 856 |
|
|
2018
Q1 | $813K | Buy |
4,979
+893
| +22% | +$146K | 0.01% | 887 |
|
|
2017
Q4 | $612K | Buy |
4,086
+1,331
| +48% | +$197K | ﹤0.01% | 952 |
|
|
2017
Q3 | $419K | Buy |
2,755
+104
| +4% | +$15.7K | ﹤0.01% | 1029 |
|
|
2017
Q2 | $342K | Buy |
2,651
+543
| +26% | +$65.4K | ﹤0.01% | 1061 |
|
|
2017
Q1 | $231K | Buy |
+2,108
| New | +$186K | ﹤0.01% | 1135 |
|
|
2016
Q2 | – | Sell |
-24,421
| Closed | -$1.94M | – | 1257 |
|
|
2016
Q1 | $1.94M | Buy |
24,421
+16,078
| +193% | +$1.45M | 0.02% | 541 |
|
|
2015
Q4 | $1.05M | Buy |
8,343
+1,207
| +17% | +$146K | 0.01% | 682 |
|
|
2015
Q3 | $743K | Sell |
7,136
-85
| -1% | -$10.9K | 0.01% | 803 |
|
|
2015
Q2 | $892K | Buy |
+7,221
| New | +$910K | 0.01% | 781 |
|
Other funds holding VRTX
VCM
VPM
Baird Financial Group's VRTX Position: Q1 2026 in Review
Baird Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 35% in Q1 2026, buying an estimated $1.05M and bringing the position to 8,771 shares worth $3.92M. The position accounts for 0.01% of the portfolio, ranked #812.
Baird Financial Group first reported a position in VRTX in Q2 2015 and has held it in 41 quarters since. The position peaked at $27.7M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Baird Financial Group held 8,771 shares of Vertex Pharmaceuticals worth $3.92M as of Q1 2026.
- Baird Financial Group bought 2,260 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
- Vertex Pharmaceuticals made up 0.01% of Baird Financial Group's portfolio in Q1 2026, its #812 holding.
- Baird Financial Group first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- Baird Financial Group's Vertex Pharmaceuticals position peaked at $27.7M in Q4 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.